SCHEMBL17788722

SCHEMBL17788722

Cc1cc(-c2ncn(C=C(C(=O)O)c3ccncc3)n2)cc(C(F)(F)F)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
XPO1 O14980 13/20 0.54
RANBP1 P43487 1/20 0.54
KCNH2 Q12809 1/20 0.54
ESR1 P03372 1/20 0.43
HTR1A P08908 1/20 0.43
PTGS1 P23219 1/20 0.43
PTGS2 P35354 1/20 0.43
HRH1 P35367 1/20 0.43
PDE4D Q08499 1/20 0.43
SLC29A1 Q99808 1/20 0.43
EGFR P00533 1/20 0.36
FGFR1 P11362 1/20 0.36
KDR P35968 1/20 0.36
KDM2B Q8NHM5 1/20 0.35
KDM4C Q9H3R0 1/20 0.35
ABL1 P00519 1/20 0.34
BCR P11274 1/20 0.34
PROKR1 Q8TCW9 1/20 0.34
ELANE P08246 1/20 0.33
PDE4B Q07343 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17788723 1.00 XPO1 (0.54) XPO1RANBP1KCNH2ESR1HTR1A
SCHEMBL17788724 1.00 XPO1 (0.54) XPO1RANBP1KCNH2ESR1HTR1A
SCHEMBL16324515 0.93 XPO1 (0.62) XPO1RANBP1KCNH2ESR1HTR1A
SCHEMBL16361563 0.93 XPO1 (0.62) XPO1RANBP1KCNH2ESR1HTR1A
SCHEMBL16324516 0.93 XPO1 (0.62) XPO1RANBP1KCNH2ESR1HTR1A
SCHEMBL17788728 0.91 XPO1 (0.67) XPO1RANBP1KCNH2ESR1HTR1A
SCHEMBL17788726 0.91 XPO1 (0.67) XPO1RANBP1KCNH2ESR1HTR1A
SCHEMBL17788725 0.91 XPO1 (0.67) XPO1RANBP1KCNH2ESR1HTR1A
SCHEMBL17788746 0.90 XPO1 (0.52) XPO1RANBP1KCNH2ESR1HTR1A
SCHEMBL17788740 0.90 XPO1 (0.52) XPO1RANBP1KCNH2ESR1HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180155317-A1 NUCLEAR TRANSPORT MODULATORS AND USES THEREOF Karyopharm Therapeutics Inc. 2018-06-07 US disclosed
US-9738624-B2 Nuclear transport modulators and uses thereof Karyopharm Therapeutics Inc. (US) 2017-08-22 US disclosed
US-20160152596-A1 Nuclear Transport Modulators and Uses Thereof Karyopharm Therapeutics Inc. (US) 2016-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180155317-A1 NUCLEAR TRANSPORT MODULATORS AND USES THEREOF XPO1, XPO5, XPOT XPO1 1/4885RANBP1 159/4885KCNH2 4379/4885
US-20160152596-A1 Nuclear Transport Modulators and Uses Thereof XPO5, XPO1, XPOT XPO1 2/4885RANBP1 144/4885KCNH2 4320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.